Tropic

Executive Summary

Tropic is a UK-based synthetic biology company that leverages CRISPR-based gene editing to engineer novel microbial strains for industrial and therapeutic applications. Founded in 2019 and headquartered in London, the company targets sustainable bio-manufacturing solutions, aiming to replace traditional chemical processes with more efficient and environmentally friendly biological alternatives. Tropic operates in the Industrial Biotechnology sector and is currently in the platform stage, indicating a focus on developing and validating its core technology rather than commercializing specific products. The company is privately held with an estimated valuation not disclosed and has raised no publicly known funding. With a small team of 1-50 employees, Tropic is positioned to address the growing demand for green chemistry and bio-based production methods, though it faces competition from established players and other synthetic biology startups. The company’s success hinges on advancing its CRISPR platform to achieve commercially viable yields and securing partnerships or funding to scale operations.

Upcoming Catalysts (preview)

• Q1 2027Series A Funding Round65% success
• Q3 2026Strategic Partnership with Chemical Manufacturer40% success
• Q4 2026Proof-of-Concept Publication in Peer-Reviewed Journal70% success